

# James N George

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/499821/publications.pdf>

Version: 2024-02-01

126  
papers

6,914  
citations

147726

31  
h-index

60583

81  
g-index

126  
all docs

126  
docs citations

126  
times ranked

4464  
citing authors

#	ARTICLE	IF	CITATIONS
1	Deletion of platelet CLEC-2 decreases GPIIb/IIIa-mediated integrin $\alpha$ IIb $\beta$ 3 activation and decreases thrombosis in TTP. <i>Blood</i> , 2022, , .	0.6	13
2	Prevalence of neuropsychiatric symptoms and stroke in patients with hereditary thrombotic thrombocytopenic purpura. <i>Blood</i> , 2022, 140, 785-789.	0.6	4
3	Thrombotic thrombocytopenic purpura: Crossing to safety. <i>Transfusion</i> , 2022, 62, 1166-1170.	0.8	0
4	TTP: the evolution of clinical practice. <i>Blood</i> , 2021, 137, 719-720.	0.6	11
5	Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28949.	0.8	13
6	Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura. <i>Blood</i> , 2021, 137, 3563-3575.	0.6	31
7	Immune Thrombocytopenia Treatment. <i>New England Journal of Medicine</i> , 2021, 385, 948-950.	13.9	14
8	Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist. <i>American Journal of Hematology</i> , 2021, 96, 1655-1665.	2.0	16
9	Long-Term Renal Outcomes in Hereditary TTP Patients: Data from the International Hereditary TTP Registry. <i>Blood</i> , 2021, 138, 770-770.	0.6	0
10	Hybrid Cross-Discipline, Interactive Curriculum to Nurture the Training Experience for Hematology-Oncology Trainees. <i>Blood</i> , 2021, 138, 2981-2981.	0.6	0
11	Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab. <i>American Journal of Hematology</i> , 2020, 95, E76-E77.	2.0	24
12	Hypertension in patients with hereditary thrombotic thrombocytopenic purpura. <i>EJHaem</i> , 2020, 1, 342-343.	0.4	4
13	Frequency and severity of pregnancy complications in women with hereditary thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2020, 95, E316-E318.	2.0	13
14	Thrombotic thrombocytopenic purpura masquerading as preclampsia with severe features at 13 weeks' gestation. <i>American Journal of Hematology</i> , 2020, 95, 1216-1220.	2.0	5
15	The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: Key findings at Enrolment until 2017. <i>Hamostaseologie</i> , 2020, 40, .	0.9	0
16	Drug-induced thrombocytopenia: 2019 Update of clinical and laboratory data. <i>American Journal of Hematology</i> , 2019, 94, E76-E78.	2.0	34
17	Maintenance rituximab for relapsing thrombotic thrombocytopenic purpura: a case report. <i>Transfusion</i> , 2019, 59, 921-926.	0.8	8
18	Caplacizumab Therapy without Plasma Exchange for Acquired Thrombotic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , 2019, 381, 92-94.	13.9	59

#	ARTICLE	IF	CITATIONS
19	Hereditary Thrombotic Thrombocytopenic Purpura. <i>New England Journal of Medicine</i> , 2019, 381, 1653-1662.	13.9	93
20	Treatment of Immune Thrombocytopenia in Adults: Version 2019. <i>Mayo Clinic Proceedings</i> , 2019, 94, 2161-2163.	1.4	0
21	Preventable deaths during initial episodes of acquired Thrombotic Thrombocytopenic Purpura: Past and future. <i>American Journal of Hematology</i> , 2019, 94, E242-E244.	2.0	0
22	Emboic stroke of undetermined source in a young woman. <i>American Journal of Hematology</i> , 2019, 94, 1044-1048.	2.0	4
23	Additional autoimmune disorders in patients with acquired autoimmune thrombotic thrombocytopenic purpura. <i>American Journal of Hematology</i> , 2019, 94, E172-E174.	2.0	17
24	Congenital TTP: toward a turning point. <i>Blood</i> , 2019, 133, 1615-1617.	0.6	2
25	Use of caplacizumab in a child with refractory thrombotic thrombocytopenic purpura. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27737.	0.8	16
26	The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. <i>Haematologica</i> , 2019, 104, 2107-2115.	1.7	99
27	American Society of Hematology 2019 guidelines for immune thrombocytopenia. <i>Blood Advances</i> , 2019, 3, 3829-3866.	2.5	684
28	Platelet sequestration and consumption in the placental intervillous space contribute to lower platelet counts during pregnancy. <i>American Journal of Hematology</i> , 2019, 94, E8-E11.	2.0	17
29	Management of antithrombotic therapy in adults with immune thrombocytopenia (ITP): a survey of ITP specialists and general hematologist-oncologists. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 46, 24-30.	1.0	11
30	Platelet Counts during Pregnancy. <i>New England Journal of Medicine</i> , 2018, 379, 1581-1582.	13.9	4
31	TTP: long-term outcomes following recovery. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 548-552.	0.9	40
32	The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective. <i>Blood Advances</i> , 2018, 2, 1510-1516.	2.5	24
33	Platelet Counts during Pregnancy. <i>New England Journal of Medicine</i> , 2018, 379, 32-43.	13.9	157
34	Drug-induced thrombotic microangiopathy: An updated systematic review, 2014-2018. <i>American Journal of Hematology</i> , 2018, 93, E241-E243.	2.0	30
35	Role of Somatic Mutations and Clonal Thrombopoiesis in Immune Thrombocytopenia. <i>Blood</i> , 2018, 132, 130-130.	0.6	1
36	Genotype-Phenotype Correlation in Congenital TTP: New Insights from a Multicentre Study with 121 Patients. <i>Blood</i> , 2018, 132, 376-376.	0.6	1

#	ARTICLE	IF	CITATIONS
37	After the Party's Over. <i>New England Journal of Medicine</i> , 2017, 376, 74-80.	13.9	16
38	Successful kidney transplantation in a patient with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). <i>Transfusion</i> , 2017, 57, 3058-3062.	0.8	4
39	Diagnosis of thrombotic thrombocytopenic purpura among patients with ADAMTS13 Activity 10%–20%. <i>American Journal of Hematology</i> , 2017, 92, E644-E646.	2.0	20
40	Rituximab for thrombotic thrombocytopenic purpura: lessons from the STAR trial. <i>Transfusion</i> , 2017, 57, 2532-2538.	0.8	18
41	A postpartum perfect storm. <i>American Journal of Hematology</i> , 2017, 92, 1105-1110.	2.0	1
42	The importance of clinical judgment for the diagnosis of thrombotic thrombocytopenic purpura. <i>Transfusion</i> , 2017, 57, 2558-2561.	0.8	7
43	Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura. <i>Kidney International Reports</i> , 2017, 2, 1088-1095.	0.4	9
44	Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. <i>Blood Advances</i> , 2017, 1, 590-600.	2.5	207
45	Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura. <i>Blood Advances</i> , 2017, 1, 2075-2082.	2.5	61
46	Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah's Witness experience. <i>Blood Advances</i> , 2017, 1, 2161-2165.	2.5	25
47	Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. <i>Blood</i> , 2016, 128, 2175-2178.	0.6	68
48	Interferon-induced thrombotic microangiopathy. <i>Blood</i> , 2016, 128, 2753-2754.	0.6	4
49	Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. <i>Blood</i> , 2016, 127, 3092-3094.	0.6	99
50	Depression in adult patients with primary immune thrombocytopenia. <i>American Journal of Hematology</i> , 2016, 91, E462-3.	2.0	8
51	Long-term outcomes of health-related quality of life following diverse thrombotic microangiopathy syndromes. <i>American Journal of Hematology</i> , 2016, 91, E278-9.	2.0	1
52	Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer. <i>Journal of Oncology Practice</i> , 2016, 12, 523-530.	2.5	64
53	Diversity and severity of adverse reactions to quinine: A systematic review. <i>American Journal of Hematology</i> , 2016, 91, 461-466.	2.0	43
54	A Prospective, Randomized Study of Cyclosporine or Corticosteroids As an Adjunct to Plasma Exchange for the Treatment of Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2016, 128, 133-133.	0.6	4

#	ARTICLE	IF	CITATIONS
55	Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology American Society of Hematology Education Program, 2015, 2015, 644-648.	0.9	79
56	Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. American Journal of Hematology, 2015, 90, 709-714.	2.0	59
57	Measuring <sc>ADAMTS</sc> 13 activity in patients with suspected thrombotic thrombocytopenic purpura: when, how, and why?. Transfusion, 2015, 55, 11-13.	0.8	29
58	The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood, 2015, 125, 1526-1531.	0.6	102
59	Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood, 2015, 125, 616-618.	0.6	282
60	Cobalamin C deficiency-associated thrombotic microangiopathy: uncommon or unrecognized?. Lancet, The, 2015, 386, 1012.	6.3	14
61	Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura. PLoS ONE, 2015, 10, e0117614.	1.1	4
62	Syndromes of Thrombotic Microangiopathy. New England Journal of Medicine, 2014, 371, 654-666.	13.9	972
63	Thrombotic Thrombocytopenic Purpura (TTP) Patient Attitudes Regarding Depression Management: a Qualitative Study. Blood, 2014, 124, 203-203.	0.6	1
64	Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: Comparison of incidence, demographic and clinical features. Pediatric Blood and Cancer, 2013, 60, 1676-1682.	0.8	193
65	Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica, 2012, 97, 297-303.	1.7	69
66	Forecasting the future for patients with hereditary TTP. Blood, 2012, 120, 243-244.	0.6	7
67	Drug-Induced Thrombocytopenia. Drug Safety, 2012, 35, 693-694.	1.4	14
68	International Registry for Patients with Hereditary Thrombotic Thrombocytopenic Purpura (TTP) â€“ Upshaw-Schulman Syndrome. Blood, 2012, 120, 4654-4654.	0.6	1
69	A case report of long-term complete remission following cessation of romiplostim dosing in a previously severe ITP patient.. Journal of Clinical Oncology, 2012, 30, e17001-e17001.	0.8	0
70	Incidence, Age, and Gender of Children with Thrombotic Thrombocytopenic Purpura (TTP) Associated with Severe, Acquired ADAMTS13 Deficiency.. Blood, 2012, 120, 2196-2196.	0.6	1
71	Management of Primary Immune Thrombocytopenia, 2012: A Survey of Oklahoma Hematologists-Oncologists. Blood, 2012, 120, 1094-1094.	0.6	0
72	Quinine-Induced Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS): Characteristic Clinical Presentation and High Risk for Chronic Kidney Disease (CKD). Blood, 2011, 118, 2216-2216.	0.6	0

#	ARTICLE	IF	CITATIONS
73	How I treat patients with thrombotic thrombocytopenic purpura: 2010. Blood, 2010, 116, 4060-4069.	0.6	415
74	Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood, 2010, 115, 1500-1511.	0.6	477
75	First Symptoms In Idiopathic Thrombotic Thrombocytopenic Purpura (TTP): What Are They and When Do They Occur?.. Blood, 2010, 116, 1427-1427.	0.6	2
76	Documentation of Fatigue In Patients with Immune Thrombocytopenic Purpura (ITP) and Its Association with Autonomic Dysfunction. Blood, 2010, 116, 570-570.	0.6	1
77	Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study. Blood, 2010, 116, 68-68.	0.6	15
78	Are Patients Who Have Recovered From ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP) at Risk for Developing Systemic Lupus Erythematosus (SLE)?.. Blood, 2010, 116, 2519-2519.	0.6	0
79	Elevated Serum Type I Interferon Activity and Type I Interferon Peripheral Blood Gene Signature In a Subset of Patients with Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura.. Blood, 2010, 116, 3694-3694.	0.6	0
80	The Utility of Bone Marrow Examinations for the Diagnosis of Immune Thrombocytopenia.. Blood, 2010, 116, 3691-3691.	0.6	0
81	Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. British Journal of Haematology, 2009, 144, 409-415.	1.2	150
82	Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology American Society of Hematology Education Program, 2009, 2009, 153-158.	0.9	203
83	The Authors's Reply. Drug Safety, 2009, 32, 708.	1.4	0
84	The Prevalence of Immune Thrombocytopenic Purpura (ITP).. Blood, 2008, 112, 1277-1277.	0.6	3
85	Long-Term Safety Profile of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP).. Blood, 2008, 112, 3415-3415.	0.6	5
86	Evaluation of Bleeding and Thrombotic Events during Long-Term Use of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura.. Blood, 2008, 112, 3422-3422.	0.6	3
87	Lower ADAMTS13 Activity and Higher Bethesda Units of Antibody Inhibitor in Early Remission Are Associated with a Higher Probability of TTP Exacerbation.. Blood, 2008, 112, 2299-2299.	0.6	0
88	What Level of Platelet Count and Symptoms Trigger Referral of Patients with Thrombocytopenia from Primary Care Physicians to Hematologists?.. Blood, 2008, 112, 4692-4692.	0.6	0
89	Self-Injection of Romiplostim by Patients with Chronic Immune Thrombocytopenic Purpura (ITP). Blood, 2008, 112, 4707-4707.	0.6	1
90	Evaluation and Management of Patients With Thrombotic Thrombocytopenic Purpura. Journal of Intensive Care Medicine, 2007, 22, 82-91.	1.3	28

#	ARTICLE	IF	CITATIONS
91	Overlapping Features of Thrombotic Thrombocytopenic Purpura and Systemic Lupus Erythematosus. Southern Medical Journal, 2007, 100, 512-514.	0.3	40
92	A disease-specific measure of health-related quality of life in adults with chronic Immune Thrombocytopenic Purpura: Psychometric testing in an open-label clinical trial. Clinical Therapeutics, 2007, 29, 950-962.	1.1	38
93	Neurocognitive Impairment Following Recovery from ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP).. Blood, 2007, 110, 1311-1311.	0.6	3
94	Detecting Drugs That Cause Thrombocytopenia: A Comparison of Three Methods: Tests for Drug-Dependent Anti-Platelet Antibodies (DDab), Published Case Reports, and Data Mining of the US FDA Adverse Event Reporting System (AERS) Database.. Blood, 2007, 110, 2087-2087.	0.6	1
95	The Frequency of Rheumatic Disease Autoantibodies in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenia Purpura (TTP).. Blood, 2007, 110, 2090-2090.	0.6	1
96	The ADAMTS13 Gene as the Immunological Culprit in Acute Acquired TTP - First Evidence of Genetic Out-Breeding Depression in Humans.. Blood, 2007, 110, 277-277.	0.6	6
97	Sporadic Bloody Diarrhea-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) in Adults in Oklahoma: Comparison to Adults with Severe Adamts13 Deficiency and to Children with Typical HUS.. Blood, 2007, 110, 1317-1317.	0.6	2
98	Drug-Associated Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS): Frequency, Presenting Features, and Clinical Outcomes.. Blood, 2007, 110, 1315-1315.	0.6	2
99	Clinical Outcomes in Patients with ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura (TTP) Who Received Platelet Transfusions (PT).. Blood, 2007, 110, 1302-1302.	0.6	0
100	Thrombotic Thrombocytopenic Purpura. New England Journal of Medicine, 2006, 354, 1927-1935.	13.9	509
101	Quinine: common remedy, serious reactions, new insights. Blood, 2006, 108, 782-783.	0.6	3
102	Evidence for a Pathophysiological Role of Anti-ADAMTS13 Antibodies Despite the Presence of Normal ADAMTS13 Activity and Presumption of an Epitope Spreading over Time in Recurrent Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2006, 108, 1067-1067.	0.6	3
103	Detecting Drugs That Cause Thrombocytopenia: A Comparison of Published Case Reports and Data Mining of the US FDA Adverse Event Reporting System (AERS) Database.. Blood, 2006, 108, 462-462.	0.6	0
104	Disseminated Malignancy Misdiagnosed as Thrombotic Thrombocytopenic Purpura: A Report of 10 Patients and a Systematic Review of Published Cases.. Blood, 2006, 108, 1062-1062.	0.6	0
105	Controlling chronic TTP. Blood, 2005, 106, 1896-1896.	0.6	2
106	Cyclosporine Alone for the Treatment of Early Recurrences of TTP.. Blood, 2005, 106, 1236-1236.	0.6	0
107	ADAMTS13 Levels Support Hypothesis of Distinct Mechanistic Pathways for Early Versus Late-Onset of Thienopyridine-Associated Thrombotic Thrombocytopenic Purpura (TTP).. Blood, 2005, 106, 60-60.	0.6	0
108	Cyclosporine and Plasma Exchange Is Superior to Corticosteroids and Plasma Exchange as Initial Therapy of TTP.. Blood, 2005, 106, 1235-1235.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Idiopathic thrombocytopenic purpura in adults: current issues for pathogenesis, diagnosis and management. <i>The Hematology Journal</i> , 2004, 5, S12-S14.	2.0	12
110	The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: a program for patient care, education and research. <i>Transfusion</i> , 2004, 44, 1384-1392.	0.8	18
111	Quebec platelet syndrome: from the bench to the family. <i>Blood</i> , 2004, 104, 8-8.	0.6	6
112	Long-Term Follow-Up of 21 Patients with Thrombotic Thrombocytopenic Purpura (TTP) and Severe ADAMTS13 Deficiency: Demonstration of Persistent ADAMTS13 Deficiency and Neurocognitive Abnormalities.. <i>Blood</i> , 2004, 104, 856-856.	0.6	2
113	The Incidence of TTP-HUS: Racial Disparity among Patients with Severe ADAMTS13 Deficiency.. <i>Blood</i> , 2004, 104, 857-857.	0.6	11
114	Thrombotic Thrombocytopenic Purpura (TTP) and Systemic Lupus Erythematosus (SLE): Distinct but Potentially Overlapping Syndromes.. <i>Blood</i> , 2004, 104, 858-858.	0.6	3
115	For low platelets, how low is dangerous?. <i>Cleveland Clinic Journal of Medicine</i> , 2004, 71, 277-278.	0.6	5
116	Initial management of immune thrombocytopenic purpura in adults: A randomized controlled trial comparing intermittent anti-D with routine care. <i>American Journal of Hematology</i> , 2003, 74, 161-169.	2.0	64
117	ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. <i>Blood</i> , 2003, 102, 60-68.	0.6	649
118	Platelets: Thrombotic Thrombocytopenic Purpura. <i>Hematology American Society of Hematology Education Program</i> , 2002, 2002, 315-334.	0.9	58
119	Drug-Induced Thrombocytopenia: An Updated Systematic Review. <i>Annals of Internal Medicine</i> , 2001, 134, 346.	2.0	31
120	Unintentional platelet removal by plasmapheresis. <i>Journal of Clinical Apheresis</i> , 2001, 16, 55-60.	0.7	27
121	The Evidence-Based Analysis of Treatment for Chronic Myeloid Leukemia: An Introduction to Its Methods and Clinical Implications. <i>Blood</i> , 1999, 94, 1515-1516.	0.6	8
122	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): A case report. , 1999, 61, 268-270.		38
123	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): A case report. <i>American Journal of Hematology</i> , 1999, 61, 268-270.	2.0	1
124	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Diagnosis and management. <i>Journal of Clinical Apheresis</i> , 1998, 13, 120-125.	0.7	50
125	Idiopathic thrombocytopenic purpura: a guideline for diagnosis and management of children and adults. <i>Annals of Medicine</i> , 1998, 30, 38-44.	1.5	54
126	Fluorescein derivatization of fibrinogen for flow cytometric analysis of fibrinogen binding to platelets. <i>Cytometry</i> , 1994, 17, 287-293.	1.8	29